NCT05445154View on ClinicalTrials.gov

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2026

Conditions
Newly Diagnosed Acute Myeloid Leukemia (AML)
Interventions
DRUG

SKLB1028 Dose Escalation

Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin

Trial Locations (1)

Unknown

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY